(MENAFN- Baystreet) Aramark Setting its Next Competition in Toronto
Redwire Gains on News
Jasper Hikes on Cell Development
Workers At
Amazon Warehouse In Quebec Form Union
Data Center Infrastructure Management
market on Track for Rapid Growth Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Monday, May 13, 2024
Legend Biotech Vaults on Quarterlies
Legend Biotech (NASDAQ:LEGN) shares picked up steam Monday, on the release of first-quarter figures.
Net loss was $59.8 million for the first quarter of 2024, compared to a net loss of $112.1 million for the first quarter of 2023. Cash and cash equivalents, time deposits, and short-term investments were $1.3 billion as of March 31, 2024.
Other highlights: Legend and Johnson & Johnson (NYSE:JNJ) entered into a Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation to supplement our existing manufacturing capabilities and increase commercial supply of CARVYKTI ®
The company also published inaugural Environmental, Social & Governance (ESG) report which aligns with the Sustainable Accounting Standards Board (SASB) Biotechnology and Pharmaceutical sector standards, shares ESG data collection and disclosure roadmap, and future growth strategy for good corporate citizenship
In December 2017, Legend Biotech entered into an exclusive worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize cilta-cel (the Janssen Agreement).
“Legend made great progress in the first quarter, culminating in our exciting announcements in recent weeks. We received label expansions for CARVYKTI in the U.S., Europe, and Brazil that have changed the treatment paradigm for multiple myeloma and will enable more patients to receive our transformative therapy earlier in the course of their disease,” said CEO Ying Huang.
LEGN shares began Monday up 46 cents, or 1.1%, to $43.70.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN13052024000212011056ID1108206465
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.